Paclitaxel-2′-ethylcarbonate prodrug can circumvent P-glycoprotein-mediated cellular efflux to increase drug cytotoxicity

被引:22
|
作者
Tanino, Tadatoshi
Nawa, Akihiro
Kondo, Eisaku
Kikkawa, Fumitaka
Daikoku, Tohru
Tsurumi, Tatsuya
Luo, ChenHong
Nishiyama, Yukihiro
Takayanagi, Yuki
Nishimori, Katuhiko
Ichida, Seiji
Wada, Tetsuyuki
Miki, Yasuyoshi
Iwaki, Masahiro
机构
[1] Kinki Univ, Sch Pharmaceut Sci, Higashiosaka, Osaka 5778502, Japan
[2] Nagoya Univ, Grad Sch Med, Shouwa Ku, Nagoya, Aichi 4668550, Japan
[3] Aichi Canc Ctr, Res Inst, Chikusa Ku, Nagoya, Aichi 4648681, Japan
[4] Okayama Univ, Sch Med, Okayama 7008558, Japan
[5] Tohoku Univ, Grad Sch Agr Sci, Sendai, Miyagi 9818555, Japan
关键词
carboxylesterase-prodrug; gene-directed enzyme prodrug therapy; growth inhibition; paclitaxel; P-glycoprotein;
D O I
10.1007/s11095-006-9171-6
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose: The aim of the study was to investigate whether 2'-ethylcarbonate-linked paclitaxel (TAX-2'-Et) circumvents P-glycoprotein (P-gp)-mediated cellular efflux and cytotoxicity enhanced by TAX-2'-Et activation within human culture cells transfected with a rabbit liver carboxylesterase (Ra-CES) cDNA. Materials and Methods: TAX-2'-Et transport was characterized in a human colon carcinoma cell line (Caco-2) and paclitaxel (TAX)-resistant ovarian carcinoma cells (SKOV3/TAX60). Expression of P-gp, multidrug resistance protein (MRP) 2 and Ra-CES was detected by Western blotting. Cytotoxicity against Ra-CES-expressing cells and cellular amount of TAX produced were determined by MTT assay and using HPLC, respectively. Results: Unlike rhodamine123 and TAX, TAX-2'-Et did not exhibit polarized transport in the Caco-2 cells in the absence or presence of verapamil. P-gp levels were expressed much higher in the SKOV3/TAX60 cells than in the Caco-2 cells. MRP2 protein was not detectable in the SKOV3/TAX60 cells. Uptake by the SKOV3/TAX60 cells was similar in quantity to the amount internalized by P-gp-negative SKOV3 cells. In the SKOV3/TAX60 cells, cellular uptake of TAX-2'-Et was not altered regardless of the absence or presence of verapamil. The cytotoxicity to the untransfected SKOV3 cells induced by TAX-2'-Et was significantly lower than that induced by TAX. In the Ra-CES-expressing SKOV3 line, the EC50 value of TAX (10.6 nM) was approximately four-fold higher than that of TAX-2'-Et (2.5 nM). Transfection of Ra-CES into another TAX-resistant ovarian carcinoma cells (KOC-7c) conferred a high level of TAX-2'-Et cytotoxicity via prodrug activation. The intracellular levels of TAX produced from TAX-2'-Et in the Ra-CES-positive KOC-7c cells significantly increased compared with the levels seen in exposure of the untransfected KOC-7c cells to TAX. Conclusions: TAX-2'-Et can circumvent P-gp-associated cellular efflux of TAX. TAX-2'-Et is converted into TAX by the Ra-CES, supporting its potential use as a theoretical GDEPT strategy for cancer cells expressing high levels of P-gp. The TAX-2'-Et prodrug efficiently increased the amount of intracellular TAX, which mediates tumor cell death.
引用
收藏
页码:555 / 565
页数:11
相关论文
共 50 条
  • [1] Paclitaxel-2′-ethylcarbonate prodrug can circumvent P-glycoprotein-mediated cellular efflux to increase drug cytotoxicity
    Nawa, Akihiro
    Tanino, Tadatoshi
    Kajiyama, Hiroaki
    Shibata, Kiyosumi
    Iwaki, Masahiro
    Kikkawa, Fumitaka
    JOURNAL OF GENE MEDICINE, 2008, 10 (04): : 475 - 476
  • [2] Paclitaxel-2′-Ethylcarbonate Prodrug Can Circumvent P-glycoprotein-mediated Cellular Efflux to Increase Drug Cytotoxicity
    Tadatoshi Tanino
    Akihiro Nawa
    Eisaku Kondo
    Fumitaka Kikkawa
    Tohru Daikoku
    Tatsuya Tsurumi
    ChenHong Luo
    Yukihiro Nishiyama
    Yuki Takayanagi
    Katuhiko Nishimori
    Seiji Ichida
    Tetsuyuki Wada
    Yasuyoshi Miki
    Masahiro Iwaki
    Pharmaceutical Research, 2007, 24 : 555 - 565
  • [3] Circumventing P-glycoprotein-mediated cellular efflux of quinidine by prodrug derivatization
    Jain, Ritesh
    Majumdar, Sountyajit
    Nashed, Yasser
    Pal, Dhananjay
    Mitra, Ashim K.
    MOLECULAR PHARMACEUTICS, 2004, 1 (04) : 290 - 299
  • [4] Kinetics of P-glycoprotein-mediated efflux of paclitaxel
    Jang, SH
    Wientjes, MG
    Au, JLS
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2001, 298 (03): : 1236 - 1242
  • [5] Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux
    Chavanpatil, Mahesh D.
    Patil, Yogesh
    Panyam, Jayanth
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2006, 320 (1-2) : 150 - 156
  • [6] Amino acid prodrug of quinidine: An approach to circumvent P-glycoprotein mediated cellular efflux
    Patel, Mitesh
    Mandava, Nanda K.
    Pal, Dhananjay
    Mitra, Ashim K.
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2014, 464 (1-2) : 196 - 204
  • [7] Can celecoxib affect P-glycoprotein-mediated drug efflux? A microPET study
    De Vries, Erik F. J.
    Doorduin, Janine
    Vellinga, Namkje A. R.
    Van Waarde, Aren
    Dierckx, Rudi A.
    Klein, Hans C.
    NUCLEAR MEDICINE AND BIOLOGY, 2008, 35 (04) : 459 - 466
  • [8] Evaluation of the Flavonoid Oroxylin A as an Inhibitor of P-Glycoprotein-Mediated Cellular Efflux
    Go, Woon Jung
    Ryu, Jong Hoon
    Qiang, Fu
    Han, Hyo-Kyung
    JOURNAL OF NATURAL PRODUCTS, 2009, 72 (09): : 1616 - 1619
  • [9] Recent progress in understanding the mechanism of P-glycoprotein-mediated drug efflux
    Loo, TW
    Clarke, DM
    JOURNAL OF MEMBRANE BIOLOGY, 2005, 206 (03): : 173 - 185
  • [10] Recent Progress in Understanding the Mechanism of P-Glycoprotein-mediated Drug Efflux
    T.W. Loo
    D.M. Clarke
    The Journal of Membrane Biology, 2005, 206 : 173 - 185